PDGFRA and gastrointestinal stromal tumor: The preliminary results of the phase I trial NAVIGATOR, presented at the Connective Tissue Oncology Meeting (CTOS) 2018, reported a total of 231 GIST patients with survival data being available for 207 patients treated in four different cohorts: (1) 20 GIST patients in second-line, (2) 23 GIST patients in third-/fourth-line regorafenib-naive, (3) 109 GIST patients in fourth or more advanced lines, and (4) 55 PDGFRA D842V-mutated GIST patients [11••].